【摘要】 目的 探讨c-Jun、EGFR的表达与乳腺癌分子分型及临床病理特征的相关性。方法 选取80例乳腺癌和癌旁组织标本，采用免疫组化、Western blot、RT-qPCR法检测c-Jun、EGFR的表达。结果 c-Jun、EGFR在乳腺癌中的表达(80%、45%)均高于癌旁组织(26%、8%),差异有统计学意义(P<0.05);c-Jun、EGFR在乳腺癌组织中的表达均与临床分期、组织学分级、淋巴结转移有关(P<0.05);乳腺癌组织中c-Jun和EGFR的表达水平呈正相关(r=0.452,P<0.05);与Luminal型乳腺癌相比，在HER-2过表达型及基底样型乳腺癌中c-Jun、EGFR表达增加，差异有统计学意义(P<0.05)。结论 c-Jun和EGFR在乳腺癌组织中高表达，且与乳腺癌分子分型、恶性程度密切相关，将为乳腺癌的诊断及治疗提供新靶点。更多还原

【Abstract】 Objective To investigate the correlation between the expression of c-Jun, EGFR and the molecular types and clinicopathological characteristics of breast cancer. Methods A total of 80 breast cancer specimens and adjacent tissues were selected as study subjects. The protein expression and mRNA cotents of c-Jun, EGFR were detected by immunohistochemistry, Western blot, and RT-qPCR. Results The expression of c-Jun and EGFR in breast cancer(80%, 45%) were higher than those in adjacent tissues(26%, 8%), and the differences were statistically significant(P<0.05). The expression of c-Jun, EGFR in breast cancer tissues were all related to clinical stage, histological grade and lymph node metastasis(P<0.05). The expression levels of c-Jun and EGFR in breast cancer tissues were positively correlated(r=0.452, P<0.05). The expression of c-Jun and EGFR in HER-2 overexpression and basal-like breast cancer were higher than in the luminal types, and the differences were statistically significant(P<0.05). Conclusion The expression of c-Jun and EGFR is higer in breast cancer tissues than those in adjacent tissues, which are closely related to the molecular classification and malignancy of breast cancer, sugeeesting that c-Jun and EGFR can be used as new targets for the diagnosis and treatment of breast cancer.更多还原